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Abstract
Introduction: Ketamine is increasingly being used in various pain settings. The purpose of this study was to
assess the effect of an analgesic dose of ketamine in the bispectral index (BIS), spectral edge frequency (SEF-95),
density spectral array (DSA), cerebral oximetry (rSO2) and mean arterial pressure (MAP) during general
anaesthesia with a target controlled infusion.
Methods: A prospective, single-blinded and randomized study on adult patients scheduled for elective spine
surgery was carried out. After anaesthesia induction with propofol, remifentanil and rocuronium, when a stable BIS
value (45-55) was achieved, an automatic recording of BIS, SEF-95, rSO2 and MAP values during 9 min was
performed to establish patients baseline values. Subsequently, patients were randomly assigned to receive a
ketamine bolus dose of 0.2 mg/kg, 0.5 mg/kg or 1 mg/kg; all variables were recorded for additional 9 min after the
ketamine bolus, in the absence of any surgical stimulus. A p-value <0.05 was considered significant in the statistical
analysis.
Results and discussion: Thirty-nine patients were enrolled in the study. Our results show a dose-related
increase of SEF-95 and BIS values. DSA demonstrate a shift in the frequency range and power distribution towards
higher frequencies. Our results do not show significant differences in MAP and rSO2 values.
Conclusion: When ketamine is used intraoperatively in analgesic doses, the anaesthetist should anticipate an
increase in SEF-95 and BIS values which will not be associated with the level of anaesthesia.
Keywords: Ketamine; Bispectral index (BIS); Spectral edge
frequencies (SEF-95); Regional cerebral oxygen saturation (rSO2);
Near-infrared spectroscopy (NIRS); Mean arterial pressure
Introduction
Ketamine was first used simply as an anaesthetic, although it is
increasingly used at sub-anaesthetic doses as an analgesic in a wide
range of pain settings, including the treatment of acute post-operative
pain [1-3]. The anti-nociceptive effect of ketamine is primarily
associated with the antagonism of the N-methyl-D-aspartate (NMDA)
receptor [2,4-6].
Published literature shows that ketamine is used in abdominal,
orthopaedic, spine and gynaecological surgery. Ketamine has
demonstrated an increase in time to first analgesic request and a
decrease in overall opioid requirement [3]. However, the use of
ketamine as an adjuvant analgesic involves different practice regarding
doses (0.15-1 mg/kg), route and time of administration [1].
Regardless of the benefits and the increasing use of ketamine, there
are some adverse effects, namely visual hallucinations, vivid dreams,
hypertension, increased cardiac output, tachycardia and tonic-clonic
movements. Ketamine produces the so-called “dissociative” anaesthetic
state and it increases cerebral metabolism, cerebral blood flow and
intracranial pressure. Moreover, it does not follow the basic anaesthesia
related electroencephalogram (EEG) pattern. Anaesthesia with
ketamine is characterized by frontally dominant theta activity with
abolition of alpha rhythms. EEG activity may be very disorganized and
variable at all doses and electrocortical silence cannot be produced.
Ketamine alone has been shown to reduce the spectral edge
frequencies (SEF-95), an effect that is driven predominantly by
increases in absolute theta band power at the expense of alpha band
power [5,7,8].
The Bispectral index (BIS), a processed index derived from raw EEG
data, is commonly used to monitor the hypnotic component of
anaesthesia. Consequently, several authors have assessed the effect of
different analgesic doses of ketamine in BIS values [9-14].
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Additionally, effects of analgesic doses of ketamine on regional
cerebral blood flow, oxygen consumption and regional cerebral blood
volume have also been evaluated. The most recent studies showed that
analgesic doses of ketamine induce a global increase in cerebral blood
flow but no changes on metabolic rate of oxygen [15,16]. However,
Engelhard et al. [17] concluded that ketamine in combination with low
dose propofol did not alter the dynamic cerebrovascular response. The
effects of analgesic doses on cerebral oxygenation using near-infrared
spectroscopy (NIRS) have not been studied yet. NIRS is a non-invasive
optical technique and current commercially available NIRS devices are
used to evaluate regional cerebral oxygen saturation (rSO2). It is not
possible to detect changes in areas located distant from the monitored
site, although global cerebral oxygen sufficiency can also be assessed
[18].
Concerning cardiovascular effects of ketamine, published data
points to its sympathomimetic effects. Nonetheless, certain
pharmacologic methods have been used to block these effects, namely
benzodiazepines and propofol [5]. Even so hemodynamic effects of
analgesic doses of ketamine have not been estimated until now in
clinical studies.
The purpose of the present study was to assess the effect of an
analgesic dose of ketamine in BIS and SEF-95 values, density spectral
array (DSA) of the EEG, rSO2 and mean arterial pressure (MAP)
during a stable target controlled infusion general anaesthesia.
Methods
The study was performed at Centro Hospitalar do Porto (CHP),
Porto, Portugal after Hospital Review Board and Ethical Committee
approvals (IRB: N/REF.ª249/13(159-DEFI/200-CES)). Written,
informed consent was obtained from all study patients.
Participants
Adult patients, ASA physical status I and II, with more than 18
years, scheduled for elective spine surgery were included.
Exclusion criteria included severe uncontrolled high blood pressure;
heart failure; cardiac ischemic disease; increased intracranial pressure;
increased intraocular pressure; hyperthyroidism or use of anti-thyroid
medications; presence of any neurological or psychiatric disease;
consumption of illicit drugs and chronic alcohol abuse; liver disease;
hypersensitivity to ketamine.
Blinding and randomization
This is a prospective, single-blind and randomized study. A random
number generator was used to randomly assign the patients into three
groups accordingly to the bolus ketamine dose (0.2, 0.5 or 1 mg/kg).
Each patient serves as his or her own control. The patients were
blinded to group assignments.
Standard anaesthetic protocol and study design
In the operating room, continuous pulse oximetry,
electrocardiography, temperature, invasive blood pressure and
neuromuscular blockade monitoring were instituted in all patients. The
BIS was monitored using a BIS VISTATM Bilateral Monitoring System
(Covidien, Colorado, US) with a bilateral sensor on the forehead of the
patient. The cerebral oximetry was monitored with INVOSTM 5100C
Cerebral/Somatic Oximeter (Covidien, Colorado, US) with two
sensors placed bilaterally on forehead. Central temperature was
likewise monitored by an oesophageal thermometer placed after
orotracheal intubation.
General anaesthesia with propofol and remifentanil was achieved
using the OrchestraTM Mobile stand (Fresenius Vial, Brézins, France)
and a rocuronium (0.6 mg/kg) initial bolus was used for
neuromuscular blockade. A continuous infusion of propofol was
started at 2000 mg/h until loss of consciousness (LOC), defined by the
clinical signs of “loss of eyelash reflex” and “loss of response to name
calling”. At LOC, the calculated effect site concentration was recorded
and the propofol infusion system was adjusted to an effect
compartment controlled infusion based on Schnider pharmacokinetic
model, according to the BIS values [19]. The infusion profile was
continued during the study period. Remifentanil infusion was adjusted
accordingly to pharmacokinetic model of Minto [20]; a 3 ng/mL effect
site concentration was established initially. After orotracheal
intubation the effect site concentration was adjusted to 1 ng/mL.
The study period started when BIS values are steady between 45 and
55, pCO2 between 34 and 42 mmHg and when mean arterial pressure
values were between a 30% interval from baseline value. BIS, SEF, rSO2
and MAP values were subsequently automatically recorded during 9
min without any surgical or noxious stimuli. During this time the drug
infusions were not changed.
Lastly, patients randomly received a bolus of ketamine 0.2 mg/Kg
(Group 1), 0.5 mg/Kg (Group 2) or 1 mg/Kg (Group 3). BIS, SEF-95,
rSO2 and MAP values were automatically recorded during further 9
min without any surgical or noxious stimuli.
All BIS and SEF-95 values, cerebral oximetry and hemodynamic
data were recorded automatically every 1, 35 and 30 s, respectively, for
18 min.
Sample size
Literature shows that mean BIS value is higher when increasing sub-
anaesthetic doses of ketamine are applied [11]. Sample size calculation
with a power of 0.80 (β of 0.2) and an α of 0.05 was performed,
considering the primary hypothesis of an increase in the BIS after the
ketamine bolus of 0.2 mg/Kg. Considering our protocol, we assumed
an average BIS value of 50 ± 3 during the 9 min before the
administration of ketamine and an increase of 6 (12%) values as
clinical significant. This resulted in a sample size of 12 patients per
group. Considering the above results and the possibility of patient
exclusion due to external complications, a total of 13 patients per
group were included in the study.
Statistical methodology
Statistical analysis was performed using IBM SPSS statistics version
22. Categorical variables are presented as frequency and percentage
and continuous variables are presented as mean ± standard deviation
(SD). The Shapiro-Wilk test was used to test for the normality of data.
ANOVA and Kruskal Wallis test were used for continuous variables;
Chi-Square test was used for categorical variables, on comparisons
between groups. Paired t-test and Wilcoxon two-sample paired signed
rank test were used for comparisons within groups. 95% confidence
intervals were estimated using bootstrapping (1000 replicates). A p-
value <0.05 was considered to be statistically significant.
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Results
Sixty-six patients were eligible for participation in the study from
December 2013 to June 2015. Twenty-seven patients were excluded,
and thirty-nine patients were recruited and assigned to a ketamine
group (Figure 1).
Figure 1: Patient enrolement.
Patient´s demographics and perioperative data are presented in
Table 1. There were no statistical significant differences between
groups except for age.
Variables Group 1 Group 2 Group 3
Age 53.77 ± 10.47 49.85 ± 12.56 43.46 ± 8.09
Gender
Female 6 7 5
Male 7 6 8
ASA
I 3 5 7
II 10 8 6
BMI 27.89 ± 4.59 27.08 ± 3.18 26.22 ± 3.60
PaCO2 37.32 ± 2.79 37.57 ± 3.89 37.95 ± 3.21
Temperature 36.22 ± 0.53 36.30 ± 0.51 36.09 ± 0.56
Data are presented as frequency or mean ± SD; ASA: American Society of
Anaesthesiology; BMI: Body Mass Index (kg/m2); PaCO2: Partial Pressure of
CO2 in the Arterial Blood (mmHg); Oesophageal Temperature (°C)
Table 1: Patient demographic characteristics and perioperative data.
Outcome variables are illustrated in tables 2-4, respectively for
group 1, 2 and 3. Only rSO2 values proved not to be normally
distributed. These tables also show BIS VISTATM monitor signal
quality indicators, namely electromyography indicator (EMG) and
signal quality indicator (SQI), which were not different among the
groups (p=0.326 and p=0.834, respectively for EMG and SQI).
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Group 1 (n=13)
Variables
Before ketamine After ketamine
Mean ± SD (95% CI) Mean ± SD (95% CI)
EMG 26.09 ± 1.14 (25.50; 26.69) 26.37 ± 1.19 (25.76; 27.01)
SQI 95.62 ± 1.93 (94.60; 96.62) 93.31 ± 5.74 (89.81; 95.76)
SEF-L 16.94 ± 1.23 (16.26; 17.55) 18.27 ± 1.44* (17.47; 19.03)
SEF-R 17.01 ± 1.19 (16.33; 17.61) 18.32 ± 1.36* (17.55; 19.03)
BIS-L 49.82 ± 4.45 (47.65; 52.41) 51.97 ± 6.97 (47.93; 55.51)
BIS-R 50.18 ± 4.30 (48.17; 52.65) 52.32 ± 7.43 (48.05; 56.07)
MAP (mmHg) 71.53 ± 7.48 (67.32; 75.45) 70.91 ± 8.32 (66.51; 75.08)
CI: Confidence Interval for the Mean; EMG: Electromyography Indicator; L: left; MAP: Mean Arterial Pressure; R: right; SD: Standard Deviation; SQI: Signal Quality
Indicator
Table 2: SEF, BIS and MAP results before and after Ketamine administration for the patients in Group 1 (Ketamine 0.2 mg/kg) (*p<0.05).
Group 2 (n=13)
Variables Before ketamine After ketamine
Mean ± SD (95% CI)
Mean ±
SD (95% CI)
EMG 25.84 ± 0.95
(25.27;
26.06)
26.28 ±
1.01
(25.62;
26.61)
SQI 94.51 ± 3.98
(91.70;
96.32)
92.27 ±
6.92
(87.38;
94.80)
SEF-L 16.86 ± 0.78
(16.48;
17.31)
19.88 ±
2.08*
(18.85;
21.06)
SEF-R 16.91 ± 0.81
(16.49;
17.37)
19.97 ±
2.14*
(18.88;
21.18)
BIS-L 50.27 ± 3.81
(47.69;
51.87)
56.74 ±
5.99*
(54.21;
60.42)
BIS-R 51.07 ± 3.86
(48.69;
52.82)
57.46 ±
7.74*
(53.98;
62.19)
MAP (mmHg) 74.84 ± 10.95
(68.71;
81.54)
74.97 ±
15.71
(66.15;
84.66)
CI: confidence Interval for the Mean; EMG: Electromyography Indicator; L: Left;
MAP: Mean Arterial Pressure; R: Right; SD: Standard Deviation; SQI: Signal
Quality Indicator
Table 3: SEF. BIS and MAP results before and after Ketamine
administration for the patients in Group 2 (Ketamine 0.5 mg/kg)
(*p<0.05).
Our results do not show statistically significant differences between
right and left side for SEF-95 and BIS values in the three groups.
Consequently, we have considered the left side values on our analysis.
With respect to group 1 (Table 2), our results show an increase of
SEF-95 value by 1.34 ± 0.99 after ketamine bolus (p<0.001). Regarding
group 2 (Table 3), our results establish an increase of SEF-95 value by
3.03 ± 2.04 (p<0.01) and an increase of BIS value by 6.65 ± 7.40
(p=0.008). The 95% CI for BIS in group 2 shows that the mean BIS
after ketamine could be 60. In group 3 (Table 4), we also find an
increase of SEF-95 and BIS values, respectively, by 3.30 ± 2.77 (p=0.01)
and 6.85 ± 10.35 (p=0.034). The 95% CI for BIS in group 3 shows that
the mean BIS after ketamine could increase to 63. DSA, in accordance
to SEF-95 and BIS values, demonstrate a shift in the frequency range
and power distribution towards higher frequencies in the three groups
(Figure 2).
Figure 2: Density Spectral Array in patient groups.
Regarding the differences between SEF-95 and BIS values in the
three groups after ketamine bolus (Table 5), our results only show a
statistically significant difference between mean SEF-95 values of
groups 1 and 2. Furthermore, attending that in clinical practice a BIS
value between 40 and 60 indicates an appropriate level for general
anaesthesia, our results shows that in group 1, there is no any patient
with a mean BIS value higher than 60. In groups 2 and 3, our results
show at least 25% and 45% patients with a mean BIS value higher than
60, respectively.
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Group 3 (n=13)
Variables
Before ketamine After ketamine
Mean ± SD (95% CI) Mean ± SD (95% CI)
EMG 26.15 ± 0.77 (25.75; 26.52) 26.87 ± 0.99
(26.37;
27.42)
SQI 94.14 ± 2.43 (92.84; 95.30) 91.89 ± 6.02
(88.35;
94.74)
SEF-L 17.21 ± 1.49 (16.40; 17.91)
20.51 ±
2.46*
(19.32;
21.93)
SEF-R 17.30 ± 1.46 (16.51; 18.04)
20.59 ±
2.39*
(19.43;
21.96)
BIS-L 51.44 ± 4.13 (49.28; 53.60)
58.29 ±
10.34*
(52.73;
63.31)
BIS-R 51.44 ± 4.52 (48.92; 53.84)
58.03 ±
11.34*
(51.53;
63.39)
MAP (mmHg) 77.74 ± 12.73 (71.28; 84.59)
78.23 ±
12.25
(72.11;
84.58)
CI: Confidence Interval for the Mean; EMG: Electromyography Indicator; L: Left;
MAP-Mean Arterial Pressure; R: Right; SD: Standard Deviation; SQI: Signal
Quality Indicator
Table 4: SEF. BIS and MAP results before and after Ketamine
administration for the patients in Group 1 (Ketamine 1 mg/kg)
(*p<0.05).
Difference=value before ketamine–value after ketamine
Ketamine group SEF-Difference BIS-Difference
Group 1 (ketamine 0.2 mg/kg) -1.34 ± 0.99 -2.15 ± 7.81
Group 2 (ketamine 0.5 mg/kg) -3.03 ± 2.04 -6.46 ± 7.40
Group 3 (ketamine 1 mg/kg) -3.30 ± 2.77 -6.85 ± 10.55
Data are presented as mean ± SD
Table 5: Differences in SEF-95 and BIS values before and after the
ketamine bolus.
Considering mean MAP values, our results do not show a statistical
significant difference in all the groups before and after the ketamine
bolus (Tables 2-4).
Variation=(Baseline-rSO2 value)/Baseline
Ketamine group rSO2-L rSO2-R
Group 1 (ketamine 0.2 mg/kg) 2.08 1.19
Group 2 (ketamine 0.5 mg/kg) 1.72 1.69
Group 3 (ketamine 1 mg/kg) 2.55 3.18
Data are presented as %. L-Left; R-Right.
Table 6: Variation in rSO2 after the ketamine bolus.
Moreover, our results show a statistically significant decrease from
baseline in right and left rSO2 values after the Ketamine bolus in all the
groups (Table 6). However, when looking at the decrease in rSO2
values relative to the pre-ketamine bolus values, these are not
significantly different between groups and they are on average 2%.
Discussion
For post-operative pain, ketamine has an opioid-sparing effect and
conceivably reduce the development of chronic post-operative pain
through NMDA receptor blockade and reduction of central
sensitization. Ketamine administrations by boluses, infusion or both,
before incision, after incision or in the post-operative period are
frequent modes of usage [1].
When used in the intra-operative period, practitioners must be
aware that the disorganization of the EEG with ketamine
administration will possibly be responsible for the failure of BIS
monitoring.
Our results show an increase in SEF-95 and BIS values related to the
bolus dose. The highest increase is seen after a ketamine bolus dose of
1 mg/kg. In fact, recent studies have shown that the ketamine effect on
EEG activity is qualitatively altered when administered in the presence
of propofol. In the presence of steady state propofol levels, ketamine is
associated with a definitive acceleration of alpha band activity,
increasing its peak frequency [21,22]. Additionally, Hirota et al. [10]
have previously showed that a ketamine bolus of 0.4 mg/kg
significantly increases the BIS values during propofol-fentanyl
anaesthesia. Vereecke et al. [9] presented the same effects on the BIS
values after a ketamine bolus of 0.4 mg/kg followed by a 1 mg/kg/h
continuous infusion. Hans et al. [13] concluded that a ketamine bolus
of 0.5 mg/kg also significantly increases the BIS values, during a
sevoflurane anaesthesia. Faraoni et al. [12] showed that a ketamine
bolus of 0.2 mg/kg administered over 5 min did not increase the BIS
value over the next 15 min, during a propofol and remifentanil target-
controlled infusion and Sengupta et al. [11] verified, more recently,
that a bolus dose of ketamine 0.2 mg/kg did not affect BIS values
during propofol-fentanyl anaesthesia whereas a bolus dose of 0.5
mg/kg increased BIS values.
With respect to cardiovascular effects of ketamine, our results do not
show a statistical significant difference in all the groups. Nevertheless,
this can be related to the lower dose of ketamine in comparison to
anaesthetic doses or to the blockade effects of propofol to the
sympathomimetic effects of ketamine.
In reference to rSO2, despite our results show a statistically
significant difference between baseline and rSO2 value after ketamine
bolus, we do not consider these deviations as clinically relevant.
Actually, specific considerations should be given only to rSO2 values
lower than 50 or to a large decrease (>20%) or increase (>10%) in rSO2
from baseline. However, it has been already published that rising doses
of powerful cortical suppressant anaesthetics as volatile halogenated
anaesthetics, barbiturate hypnotics and propofol may rise rSO2 as
oxygen consumption is decreased [23]. Consequently, co-
administration of analgesic doses of ketamine and propofol could have
opposite effects on rSO2 and because of that our results only show a
small variation of rSO2 values. Additionally, it has also been published,
recently, that the increase of inspired oxygen fraction and end-tidal
CO2 resulted in a significant increase in rSO2 in patients anesthetized
in the beach chair position and that appeared to be independent of
anaesthetic choice (desflurane or total intravenous anaesthesia with
propofol) [24].
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There are potential limitations associated to our study. Firstly, the
duration of effects of ketamine on study variables after a single bolus
was not quantified. In order to avoid the influence of surgical
stimulation on the EEG cortical measurements, we conducted our
study before the surgery start, resulting in a rather limited time to
collect data. Additionally, an awareness specific questionnaire at the
end of surgery was not carried out. Nonetheless, regarding this final
limitation, as the propofol and remifentanil doses before the ketamine
bolus were maintained after testing bolus dose administration and also,
considering that no external stimuli was done to the patient, the level
of anaesthesia after ketamine bolus was possibly the same in
comparison to the level of anaesthesia before ketamine bolus.
Conclusion
This study shows that when ketamine is used intraoperatively in
analgesic doses, during an intravenous target controlled-infusion of
propofol and remifentanil, the anaesthetist should anticipate a dose-
related increase in SEF-95 and BIS values higher than 60 in some
patients, depending on the dose administered, which will not be
associated with the level of hypnosis. Furthermore, changes in the
power distribution pattern in the spectral matrix of the EEG should
also be expected. With respect to cerebral perfusion/oxygenation and
cardiovascular effects of ketamine, our results do not show significant
differences in all the groups, supporting the idea of mantained
metabolic and cerebral blood flow coupling in this ketamine dose
setting.
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